Abstract

Chronic obstructive pulmonary disease (COPD) is the third driving reason for death around the world. While COPD is a respiratory illness having various aetiologies especially ceaseless infection, a considerable number of patients experience the ill effects of exacerbation. Extreme exacerbation is identified with an altogether more regrettable result. This survey sums up the present information on the various parts of COPD exacerbations and acute respiratory failure in COPD patients with COVID-19. The effect of hazardous factors and triggers, for example, smoking, extreme wind current restriction, bronchiectasis, bacterial and viral contaminations, and comorbidities is talked about. Increasingly serious exacerbations ought to be treated with β-agonists and anticholinergics just as foundational corticosteroids. Anti-microbial treatment should just be given to patients with assumed bacterial contamination. Non-invasive ventilation is demonstrated in patients with respiratory disappointment. Treatment of hypoxemia and hypercapnia lessen the pace of COPD intensifications.

In December 2019, a flare-up of coronavirus disease 2019 (COVID-19) was recognized in Wuhan, China. The World Health Organization (WHO) pronounced this episode a noteworthy danger to worldwide wellbeing. COVID-19 is exceptionally irresistible and can prompt lethal comorbidities particularly in chronic obstructive pulmonary disease (COPD) patients. Consequently, completely understanding the qualities of COVID-19 in patients with (COPD) is helpful for early distinguishing proof and appropriate treatment. The clinical indications were generally mellow in some COVID-19 patients, which was conflicting with the seriousness of research facility and imaging discoveries. The seriousness was re-imagined into three phases as per its particularity: gentle, mellow moderate, and moderate-extreme. The almost certain reason for death is serious respiratory failure. Along these lines, the planning of intrusive mechanical ventilation is significant. The impacts of corticosteroids in COVID-19-(COPD) patients were helpful to some point. 

Keywords: COPD (Chronic Obstructive Pulmonary Disease); COVID-19

References

1. Vestbo J., et al. “Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 1. GOLD executive summary”. American Journal of Respiratory and Critical Care Medicine 4 (2013): 347-365.
2. Román Sánchez P., et al. “Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease”. Thorax 60 (2005): 925-931.
3. Martinez FJ., et al. “Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD executive summary”. European Respiratory Journal 49 (2017): 1700214.
4. Albert RK., et al. “Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline”. European Respiratory Journal 50 (2017): 1602265.
5. Van Le H., et al. “Risk of pneumonia with inhaled corticosteroid versus long-acting bronchodilator regimens in chronic obstructive pulmonary disease: a new-user cohort study”. PLoS One 9 (2014): e97149.
6. Anzueto A., et al. “Antibiotics for treatment and prevention of exacerbations of chronic obstructive pulmonary disease”. Journal of Infection 67 (2013): 497-515.
7. Köhler D., et al. “Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, multicentre, randomized, controlled clinical trial”. The Lancet Respiratory Medicine 2 (2014): 698-705.
8. Strange C., et al. “Effect of endobronchial coils vs usual care on exercise tolerance in patients with severe emphysema: the RENEW randomized clinical trial”. The Journal of the American Medical Association 315 (2016): 2178-2189.
9. World Health Organization. “Coronavirus disease (COVID-19)” (2020).
10. Lippi G and Henry BM. “Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019”. Research Medicine (2020).
11. Guan WJ., et al. “Clinical characteristics of coronavirus disease 2019 in China”. The New England Journal of Medicine (2020).
12. Phan LT., et al. “Importation and human-to-human transmission of a novel coronavirus in Vietnam”. The New England Journal of Medicine 9 (2020): 872-874.
13. Chen N., et al. “Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study”. Lancet 10223 (2020): 507.
14. Jeffery PK. “Differences and similarities between chronic obstructive pulmonary disease and asthma”. Clinical and Experimental Allergy 29 (1999): 14-26.
15. Chung M., et al. “CT imaging features of 2019 novel coronavirus (2019-nCoV)”. Radiology 1 (2020): 202-207.
16. Ranieri VM., et al. “Acute respiratory distress syndrome: the Berlin definition”. The Journal of the American Medical Association 307 (2012): 2526-2533.
17. Donaldson GC., et al. “Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease”. Thorax10 (2002): 847-852.
18. Soler-Cataluña JJ., et al. “Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease”. Thorax 11 (2005): 925-931.
19. West JB. “Causes of and compensations for hypoxemia and hypercapnia”. Comprehensive Physiology 3 (2011): 1541-1553.
20. Quintana JM., et al. “Predictive score for mortality in patients with COPD exacerbations attending hospital emergency departments”. BMC Medicine 12 (2014): 66.
21. Barberà JA., et al. “Mechanisms of worsening gas exchange during acute exacerbations of chronic obstructive pulmonary disease”. European Respiratory Journal 6 (1997):1285-1291.
22. Ou X., et al. “Effect of high-flow nasal cannula oxygen therapy in adults with acute hypoxemic respiratory failure: a meta-analysis of randomized controlled trials”. Canadian Medical Association Journal 189 (2017): E260-E267.
23. Meduri GU., et al. “Prolonged low-dose methylprednisolone treatment is highly effective in reducing the duration of mechanical ventilation and mortality in patients with ARDS”. Journal of Intensive Care Medicine 6 (2018): 53.
24. Wang D., et al. “Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China”. The Journal of the American Medical Association (2020).
25. Huang C., et al. “Clinical features of patients with 2019 novel coronavirus in Wuhan, China”. Lancet 10223 (2020): 497-506.
26. Xu Z., et al. “Pathological findings of COVID-19 associated with acute respiratory distress syndrome”. The Lancet Respiratory Medicine (2020).
27. World Health Organization. “Clinical Management of Severe Acute Respiratory Infection when CoViD-19 Is Suspected” (2020).
28. Zhou P., et al. “A pneumonia outbreak associated with a new coronavirus of probable bat origin”. Nature7789 (2020): 270-273.
29. Jackson DJ and Johnston SL. “The role of viruses in acute exacerbations of asthma”. The Journal of Allergy and Clinical Immunology 6 (2010): 1178-1189.
30. Mohan A., et al. “Prevalence of viral infection detected by PCR and RT-PCR in patients with acute exacerbation of COPD: a systematic review”. Respirology 3 (2010): 536-542.
31. Proud D and Chow CW. “Role of viral infections in asthma and chronic obstructive pulmonary disease”. American Journal of Respiratory Cell and Molecular Biology 5 (2006): 513‐518.
32. Global Initiative for Chronic Obstructive Lung Disease (Gold) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2020).
33. Calzetta L., et al. “Withdrawal of inhaled corticosteroids in COPD: a meta-analysis”. Pulmonary Pharmacology and Therapeutics 45 (2017): 148-158.
34. Alía I., et al. “Efficacy of corticosteroid therapy in patients with an acute exacerbation of chronic obstructive pulmonary disease receiving ventilatory support”. Archives of Internal Medicine 21 (2011): 1939-1946.
35. Jackson DJ and Johnston SL. “The role of viruses in acute exacerbations of asthma”. The Journal of Allergy and Clinical Immunology 6 (2010): 1178-1189.
36. Kaiser UB., et al. “Our response to COVID-19 as endocrinologists and diabetologists”. The Journal of Clinical Endocrinology and Metabolism 5 (2020): dgaa148.
37. Wu C., et al. “Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China”. JAMA Internal Medicine (2020).